Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 10/20 | 0.40 |
| ▸ | ACACA | Q13085 | 9/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CYP46A1 | Q9Y6A2 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 2/20 | 0.31 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3494665 | 1.00 | ACACB (0.40) | ACACBACACAATMCYP46A1MEN1 | |
| SCHEMBL3490732 | 0.94 | ACACB (0.40) | ACACBACACAATMCYP46A1MEN1 | |
| SCHEMBL3490730 | 0.94 | ACACB (0.40) | ACACBACACAATMCYP46A1MEN1 | |
| SCHEMBL3492830 | 0.91 | ACACB (0.52) | ACACBACACA | |
| SCHEMBL3492828 | 0.91 | ACACB (0.52) | ACACBACACA | |
| SCHEMBL13340541 | 0.90 | ACACB (0.39) | ACACBACACAATM | |
| SCHEMBL3492172 | 0.89 | ACACB (0.37) | ACACBACACATSHRBTKALDH1A1 | |
| SCHEMBL3492176 | 0.89 | ACACB (0.37) | ACACBACACATSHRBTKALDH1A1 | |
| SCHEMBL3492877 | 0.87 | ATM (0.33) | ACACBACACAATMCYP46A1MEN1 | |
| SCHEMBL3494182 | 0.85 | ACACB (0.35) | ACACBACACAMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2123652-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | ACACA, ACAT1, CPT1B | ACACB 5/4885ACACA 1/4885ATM 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.